Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Clinical Trial ID NCT01285609

PubWeight™ 42.28‹?›

🔗 Visit the page for NCT01285609

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
2 Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013 2.03
3 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
4 CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 2013 1.71
5 What have we learned from cancer immunotherapy in the last 3 years? J Transl Med 2014 1.52
6 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
7 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
8 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
9 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
10 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
11 Targeted therapies in development for non-small cell lung cancer. J Carcinog 2013 1.12
12 Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol 2013 1.05
13 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
14 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
15 Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013 0.96
16 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
17 Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013 0.94
18 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
19 Immunotherapy for Lung Cancer: Has it Finally Arrived? Front Oncol 2014 0.94
20 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
21 Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 2016 0.89
22 Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. Invest New Drugs 2015 0.88
23 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
24 ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol 2016 0.86
25 Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 2013 0.85
26 Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014 0.85
27 Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2014 0.82
28 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.82
29 The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist 2015 0.81
30 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
31 What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013 0.81
32 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.80
33 Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol 2014 0.80
34 Cellular and molecular immunology of lung cancer: therapeutic implications. Expert Rev Clin Immunol 2014 0.79
35 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
36 Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 2016 0.78
37 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
38 Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol 2016 0.77
39 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
40 The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Ann Transl Med 2016 0.76
41 Recent advances in immunotherapy for non-small-cell lung cancer. Hum Vaccin Immunother 2013 0.76
42 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
Next 100